Key result
Plasma atrial natriuretic peptide levels were elevated before hemodialysis (353 pg/ml) and hemofiltration (337 pg/ml) and fell during treatment, with no difference between the two modalities.
Why the study?
Does hemodialysis or hemofiltration affect plasma levels of atrial natriuretic peptide in patients with end-stage renal disease?
Population
8 patients with end-stage renal disease treated with chronic hemodialysis or hemofiltration
Comparison
Hemodialysis vs Hemofiltration (cross-over protocol)
Design
Other
Follow-up
one week
Authors
Loading...
ANP may track volume changes during dialysis in ESRD; hypothesis-generating for clinical use pending prospective validation.
Observational (n=8)
Does hemodialysis or hemofiltration affect plasma levels of atrial natriuretic peptide in patients with end-stage renal disease?
Absolute Event Rate: 353% vs 337%
Plasma ANP levels are elevated in ESRD patients and decrease during dialysis, suggesting ANP may be a useful biomarker for assessing volume status in this population.
Gröll et al. (1989) conducted an observational in end-stage renal disease (n=8). Hemodialysis vs. Hemofiltration was evaluated on Mean plasma alpha-hANP levels before session (pg/ml). Plasma atrial natriuretic peptide levels were elevated before hemodialysis (353 pg/ml) and hemofiltration (337 pg/ml) and fell during treatment, with no difference between the two modalities.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: